Lung Foundation Australia is aware of concerns about industry partner funding potentially enabling undue influence.
Lung Foundation Australia works with a wide range of companies in industry with no preference given to any one company. We will not promote, endorse or favour any particular company or product.
We have established policies to ensure that we retain full independence in considering all proposals, and this policy can be read in full here.
This policy ensures we clearly document contracts that specify our independence, and we offer no exclusive arrangements with industry partners.
As a not-for-profit organisation, we are predominately supported by community donations, and less than 3% from government funding. Lung Foundation Australia must seek funding to support education programs and research activities to achieve its mission and to deliver better outcomes for patients.
We are proud to receive industry partner funding and carefully consider all sponsorship opportunities. We operate with independent consumer and advisory committees. All content and materials are developed strictly based on evidence, and they undergo a clinical review process to ensure accuracy, relevance and independence. Equally, we make comments on new treatments based on scientific evidence.
Lung Foundation Australia covers over 30 types of lung diseases, from common lung diseases such as lung cancer and Chronic Obstructive Pulmonary Disease (COPD), to those that are rarer, including Pulmonary Arterial Hypertension (PAH) and Idiopathic Pulmonary Fibrosis (IPF). We promote equitable access to treatment and evidence-based care.
Lung cancer is the leading cause of death from cancer in Australia, however research funding for lung cancer is disproportionately low – in total less than 5% of all cancer research funding.
Lung Foundation Australia complies with ACNC reporting requirements and is transparent with financials, offered freely for public review via our Annual Report.